Emerging nanoparticles for glioblastoma: Engineering precision across the blood-brain barrier
DOI:
https://doi.org/10.53992/njns.v11i2.331Keywords:
Glioblastoma, Nanoparticles, Blood-Brain Barrier, Nanotechnology, Nanomedicine, NanotherapeuticsAbstract
Glioblastoma (GBM) remains one of the most lethal brain malignancies, characterized by aggressive invasion, therapeutic resistance and poor prognosis. Conventional treatment approaches are limited by systemic toxicity, poor blood–brain barrier (BBB) penetration and lack of tumor specificity. Nanoparticle-based therapeutics offer a transformative paradigm redefining drug delivery, diagnostics and multimodal strategies in GBM. In this review, we critically explore a diverse variety of advanced nanocarrier platforms designed for anti-proliferative, radiosensitizing and immunomodulatory interventions. These systems enhance BBB penetration, tumor localization and enable co-delivery of chemotherapeutics, gene therapies and imaging agents with high precision. Innovative approaches show efficacy against glioma stem cells, modulate the tumor microenvironment and address resistance mechanisms. Integration with radiotherapy and immunotherapy yields synergistic tumor suppression and immune activation, advancing personalized nanomedicine. Despite these advancements, translational hurdles remain nanogenotoxicity, long-term biosafety, immune responses and regulatory barriers. This review emphasizes such challenges while identifying opportunities for strategic innovation in GBM nanotherapy. By uniquely bridging preclinical advances with emerging clinical perspectives, we highlight its distinct contribution within the field. By bridging nanotechnology, molecular oncology and bioengineering, we highlight how rational nanoparticle design can shift GBM management toward targeted, multimodal precision therapy, offering renewed hope against one of oncology’s most intractable diseases.
Keywords: Glioblastoma, Nanoparticles, Blood-Brain Barrier, Nanotechnology, Nanomedicine, Nanotherapeutics.
References
Wirsching HG, Galanis E, Weller M. Glioblastoma. Handb Clin Neurol. 2016;134:381-397.
Berger TR, Wen PY, Lang-Orsini M, Chukwueke UN. World Health Organization 2021 Classification of Central Nervous System Tumors and Implications for Therapy for Adult-Type Gliomas: A Review. JAMA Oncol. 2022;8(10):1493-1501.
United Kingdom National Health Service. Brain tumours. 2023. Available from: https://www.nhs.uk/ conditions/brain-tumours/.
Cancer Research UK. Glioblastoma.
[cited 2025 March 30]. Available from:https://www.cancerresearchuk. org/about-cancer/brain tumours/types/ glioblastoma.
Valenzuela-Fuenzalida JJ, Moyano-Valarezo L, Silva-Bravo V, Milos-Brandenberg D, Orellana-Donoso M, Nova-Baeza P, et al. Association between the Anatomical Location of Glioblastoma and Its Evaluation with Clinical Considerations: A Systematic Review and Meta-Analysis. J Clin Med. 2024;13(12):3460.
Rong L, Li N, Zhang Z. Emerging therapies for glioblastoma: current state and future directions. 2022;41(1):142.
Hochberg F, Toniolo P, Cole P, Salcman M. Nonoccupational risk indicators of glioblastoma in adults. J Neurooncol. 1990;8(1):55-60.
Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, et al. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012. Neurooncol. 2015;17 (Suppl 4):iv1-iv62.
Alifieris C, Trafalis DT. Glioblastoma multiforme: Pathogenesis and treatment. Pharmacol Ther. 2015;152: 63-82.
Davis ME. Glioblastoma: Overview of Disease and Treatment. Clin J Oncol Nurs. 2016;20(5 Suppl):S2-S8.
Posti JP, Bori M, Kauko T, Sankinen M, Nordberg J, Rahi M, et al. Presenting symptoms of glioma in adults. Acta Neurol Scand. 2015;131(2):88-93.
Mondal A, Kumari Singh D, Panda S, Shiras A. Extracellular Vesicles As Modulators of Tumor Micro-environment and Disease Progression in Glioma. Front Oncol. 2017;7:144.
Sizoo EM, Braam L, Postma TJ, Pasman HR, Heimans JJ, Klein M, et al. Symptoms and problems in the end-of-life phase of high-grade glioma patients. Neurooncol. 2010;12(11): 1162-1166.
Kesari S, editor. Understanding glioblastoma tumor biology: the potential to improve current diagnosis and treatments. Seminars in oncology. Elsevier; 2011.
Nam L, Coll C, Erthal LCS, De la Torre C, Serrano D, Martínez-Máñez R, et al. Drug Delivery Nanosystems for the Localized Treatment of Glioblastoma Multiforme. Materials. 2018;11(5):779.
Lima FR, Kahn SA, Soletti RC, Biasoli D, Alves T, da Fonseca ACC, et al. Glioblastoma: therapeutic challenges, what lies ahead. Biochim Biophys Acta Rev Cancer. 2012;1826(2):338-349.
Janjua TI, Rewatkar P, Ahmed-Cox A, Saeed I, Mansfeld FM, Kulshreshtha R, et al. Frontiers in the treatment of glioblastoma: Past, present and emerging. Adv Drug Deliv Rev. 2021;171:108-138.
Cohen MH, Johnson JR, Pazdur R. Food and Drug Administration Drug Approval Summary: Temozolomide Plus Radiation Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme. Clin Cancer Res. 2005;11(19):6767-6771.
Mittal S, Klinger NV, Michelhaugh SK, Barger GR, Pannullo SC, Juhász C. Alternating electric tumor treating fields for treatment of glioblastoma: rationale, preclinical, and clinical studies. J Neurosurg. 2018;128(2):414-421.
Ostrom QT, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J, et al. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007–2011. Neurooncol. 2014;16(Suppl 4):iv1-iv63.
Rapp M, Baernreuther J, Turowski B, Steiger H-J, Sabel M, Kamp MA. Recurrence Pattern Analysis of Primary Glioblastoma. World Neurosurg. 2017;103:733-740.
Arvanitis CD, Ferraro GB, Jain RK. The blood–brain barrier and blood–tumour barrier in brain tumours and metastases. Nat Rev Cancer. 2020;20 (1):26-41.
Cui J, Xu Y, Tu H, Zhao H, Wang H, Di L, et al. Gather wisdom to overcome barriers: Well-designed nano-drug delivery systems for treating gliomas. Acta Pharm Sin B. 2022;12(3):1100-1125.
Pardridge WM. The blood-brain barrier and neurotherapeutics. NeuroRx. 2005;2(1):1-2.
Narsinh KH, Perez E, Haddad AF, Young JS, Savastano L, Villanueva-Meyer JE, et al. Strategies to Improve Drug Delivery Across the Blood–Brain Barrier for Glioblastoma. Curr Neurol Neurosci Rep. 2024;24(5):123-139.
Iturrioz-Rodríguez N, Bertorelli R, Ciofani G. Lipid-Based Nanocarriers for The Treatment of Glioblastoma. Adv NanoBiomed Res. 2021;1(2): 2000054.
Meyers JD, Tennyson D, Clemens B, Basilion JP. Nanoparticles for Imaging and Treating Brain Cancer. Nano-medicine. 2013;8(1):123-143.
Saraiva C, Praça C, Ferreira R, Santos T, Ferreira L, Bernardino L. Nanoparticle-mediated brain drug delivery: Overcoming blood–brain barrier to treat neurodegenerative diseases. J Control Release. 2016;235:34-47.
Farhoudi M, Sadigh-Eteghad S, Mahmoudi J, Farjami A, Mahmoudian M, Salatin S. The Therapeutic Benefits of Intravenously Administrated Nanoparticles in Stroke and Age-related Neurodegenerative Diseases. Curr Pharm Des. 2022;28(24):1985-2000.
Raj S, Khurana S, Choudhari R, Kesari KK, Kamal MA, Garg N, et al. Specific targeting cancer cells with nanoparticles and drug delivery in cancer therapy. Semin Cancer Biol. 2021;69:166-177.
Manzari-Tavakoli A, Babajani A, Tavakoli MM, Safaeinejad F, Jafari A. Integrating natural compounds and nanoparticle-based drug delivery systems: A novel strategy for enhanced efficacy and selectivity in cancer therapy. Cancer Med. 2024;13(5): e7010.
Saleh TA. Trends in nanomaterial types, synthesis methods, properties and uses: Toxicity, environmental concerns and economic viability. Nano-Struct Nano-Objects. 2024;37:101109.
Sun L, Liu H, Ye Y, Lei Y, Islam R, Tan S, et al. Smart nanoparticles for cancer therapy. Signal Transduct Target Ther. 2023;8(1):418.
Ruiz-Garcia H, Ramirez-Loera C, Malouff TD, Seneviratne DS, Palmer JD, Trifiletti DM. Novel Strategies for Nanoparticle-Based Radiosensitization in Glioblastoma. Int J Mol Sci. 2021;22(18):9673.
Musielak E, Krajka-Kuźniak V. Lipidic and Inorganic Nanoparticles for Targeted Glioblastoma Multiforme Therapy: Advances and Strategies. Micro. 2025;5(1):2.
Trivedi MS. Role of nanostructures and immunotherapies in management of glioblastoma multiforme: Current perspectives and challenges. Asian J Pharm. 2021;15(4).
Ghaznavi H, Afzalipour R, Khoei S, Sargazi S, Shirvalilou S, Sheervalilou R. New insights into targeted therapy of glioblastoma using smart nanoparticles. Cancer Cell Int. 2024;24(1):160.
Rezaei V, Amir R, Khademi F. Glioblastoma multiforme: a glance at advanced therapies based on nanotechnology. J Chemother. 2020;32(3):107-117.
Wu Q, Berglund AE, Etame AB. The Impact of Epigenetic Modifications on Adaptive Resistance Evolution in Glioblastoma. Int J Mol Sci. 2021;22(15):8324.
Kanu OO, Hughes B, Di C, Lin N, Fu J, Bigner DD, et al. Glioblastoma Multiforme Oncogenomics and Signaling Pathways. Clin Med Oncol. 2009;3:CMO.S1008.
Ohgaki H, Kleihues P. The Definition of Primary and Secondary Glioblastoma. Clin Cancer Res. 2013; 19(4):764-772.
Aldape K, Zadeh G, Mansouri S, Reifenberger G, von Deimling A. Glioblastoma: pathology, molecular mechanisms and markers. Acta Neuropathol. 2015;129(6):829-848.
Bergström T, Forsberg-Nilsson K. Neural stem cells: Brain building blocks and beyond. Upsala J Med Sci. 2012;117(2):132-142.
Verdugo E, Puerto I, Medina MÁ. An update on the molecular biology of glioblastoma, with clinical implications and progress in its treatment. Cancer Commun. 2022;42(11):1083-1111.
Tang J, Karbhari N, Campian JL. Therapeutic Targets in Glioblastoma: Molecular Pathways, Emerging Strategies, and Future Directions. Cells. 2025;14(7):494.
Kowalski-Chauvel A, Lacore MG, Arnauduc F, Delmas C, Toulas C, Cohen-Jonathan-Moyal E, et al. The m6A RNA Demethylase ALKBH5 Promotes Radioresistance and Invasion Capability of Glioma Stem Cells. Cancers. 2021;13(1):40.
Loras A, Gonzalez-Bonet LG, Gutierrez-Arroyo JL, Martinez-Cadenas C, Marques-Torrejon MA. Neural Stem Cells as Potential Glioblastoma Cells of Origin. Life. 2023;13(4):905.
Ah-Pine F, Khettab M, Bedoui Y, Slama Y, Daniel M, Doray B, et al. On the origin and development of glioblastoma: multifaceted role of perivascular mesenchymal stromal cells. Acta Neuropathol Commun. 2023;11(1):104.
Appin CL, Brat DJ. Molecular Genetics of Gliomas. Cancer J. 2014;20(1):66-72.
Ma X, Sun C, Ding X, Xu J, Zhang Y, Deng T, et al. Mechanism analysis and targeted therapy of IDH gene mutation in glioma. Am J Cancer Res.
;15(1):248-270.
Wang H-Y, Tang K, Liang T-Y, Zhang W-Z, Li J-Y, Wang W, et al. The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas. J Exp Clin Cancer Res. 2016;35(1):86.
Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462(7274):739-744.
Gross S, Cairns RA, Minden MD, Driggers EM, Bittinger MA, Jang HG, et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med. 2010;207(2):339-344.
Gullick WJ, Marsden JJ, Whittle N, Ward B, Bobrow L, Waterfield MD. Expression of Epidermal Growth Factor Receptors on Human Cervical, Ovarian, and Vulval Carcinomas. Cancer Res. 1986;46(1):285-292.
Inal C, Emrullah Y, Bilal P, Roman P-S, Cheng H. Emerging treatment for advanced lung cancer with EGFR mutation. Expert Opin Emerg Drugs. 2015;20(4):597-612.
Siegelin MD, Borczuk AC. Epidermal growth factor receptor mutations in lung adenocarcinoma. Lab Invest. 2014;94(2):129-137.
De Luca A, Normanno N. Predictive Biomarkers to Tyrosine Kinase Inhibitors for the Epidermal Growth Factor Receptor in Non-Small-Cell Lung Cancer. Curr Drug Targets. 2010;11(7):851-864.
Li AR, Chitale D, Riely GJ, Pao W, Miller VA, Zakowski MF, et al. EGFR Mutations in Lung Adenocarcinomas: Clinical Testing Experience and Relationship to EGFR Gene Copy Number and Immunohistochemical Expression. J Mol Diagn. 2008;10(3):242-248.
Jung MJ, Woo CG, Lee S, Chin S, Kim HK, Kwak JJ, et al. Gene copy number variation and protein overexpression of EGFR and HER2 in distal extrahepatic cholangiocarcinoma. Pathology. 2017;49(6):582-588.
Birkman E-M, Ålgars A, Lintunen M, Ristamäki R, Sundström J, Carpén O. EGFR gene amplification is relatively common and associates with outcome in intestinal adenocarcinoma of the stomach, gastro-oesophageal junction and distal oesophagus. BMC Cancer. 2016;16(1):406.
Libermann TA, Nusbaum HR, Razon N, Kris R, Lax I, Soreq H, et al. Amplification and overexpression of the egf receptor gene in primary human glioblastomas. J Cell Sci. 1985;1985(Suppl 3):161-172.
Alexandru O, Purcaru SO, Tataranu LG, Lucan L, Castro J, Folcuţi C, et al. The Influence of EGFR Inactivation on the Radiation Response in High Grade Glioma. Int J Mol Sci. 2018;19(1):229.
Ekstrand AJ, Sugawa N, James CD, Collins VP. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc Natl Acad Sci U S A. 1992;89(10):4309-4313.
Yamazaki H, Yasuhisa F, Yoshito U, Norikazu T, Tomoyuki K, Shigehiko T, et al. Amplification of the Structurally and Functionally Altered Epidermal Growth Factor Receptor Gene (c-erbB) in Human Brain Tumors. Mol Cell Biol. 1988;8(4):1816-1820.
Ramnarain DB, Park S, Lee DY, Hatanpaa KJ, Scoggin SO, Otu H, et al. Differential Gene Expression Analysis Reveals Generation of an Autocrine Loop by a Mutant Epidermal Growth Factor Receptor in Glioma Cells. Cancer Res. 2006;66(2):867-874.
Ohgaki H, Kleihues P. Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci. 2009;100(12):2235-2241.
Kita D, Yonekawa Y, Weller M,
Ohgaki H. PIK3CA alterations in primary (de novo) and secondary glioblastomas. Acta Neuropathol. 2007;113(3):295-302.
Stiles BL. Phosphatase and tensin homologue deleted on chromosome 10: Extending its PTENtacles. Int J Biochem Cell Biol. 2009;41(4):757-761.
Hashemi M, Etemad S, Rezaei S, Ziaolhagh S, Rajabi R, Rahmanian P, et al. Progress in targeting PTEN/PI3K/Akt axis in glioblastoma therapy: Revisiting molecular interactions. Biomed Pharmacother. 2023;158:114204.
García-Montaño LA, Muñoz YL, Martinez F, Gallegos K, Kang H, Piccirillo SG. Abstract 544: Dissecting the functional impairment of wild-type Tp53 in human glioblastoma. Cancer Res. 2023;83(7 Suppl):544.
Zhang Y, Dube C, Gibert M, Cruickshanks N, Wang B, Coughlan M, et al. The p53 Pathway in Glioblastoma. Cancers. 2018;10(9):297.
Wade M, Li Y-C, Wahl GM. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer. 2013;13(2):83-96.
Kastenhuber ER, Lowe SW. Putting p53 in Context. Cell. 2017;170 (6):1062-1078.
Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A. 2013;110(15):6021-6026.
Pierini T, Nardelli C, Lema Fernandez AG, Pierini V, Pellanera F, Nofrini V, et al. New somatic TERT promoter variants enhance the Telomerase activity in Glioblastoma. Acta Neuropathol Commun. 2020;8(1):145.
Philpott C, Tovell H, Frayling IM, Cooper DN, Upadhyaya M. The NF1 somatic mutational landscape in sporadic human cancers. Hum
Genomics. 2017;11(1):13.
Shahcheraghi SH, Tchokonte-Nana V, Lotfi M, Lotfi M, Ghorbani A, Sadeghnia HR. Wnt/beta-catenin and PI3K/Akt/mTOR Signaling Pathways in Glioblastoma: Two Main Targets for Drug Design: A Review. Curr Pharm Des. 2020;26(15):1729-1741.
Barzegar Behrooz A, Talaie Z, Jusheghani F, Łos MJ, Klonisch T, Ghavami S. Wnt and PI3K/Akt/mTOR Survival Pathways as Therapeutic Targets in Glioblastoma. Int J Mol Sci. 2022;23(3):1353.
Wang S, Gu S, Chen J, Yuan Z, Liang P, Cui H. Mechanism of Notch Signaling Pathway in Malignant Progression of Glioblastoma and Targeted Therapy. Biomolecules. 2024;14(4):480.
Sharma P, Aaroe A, Liang J, Puduvalli VK. Tumor microenvironment in glioblastoma: Current and emerging concepts. Neurooncol Adv. 2023;5(1).
Tamai S, Ichinose T, Tsutsui T, Tanaka S, Garaeva F, Sabit H, et al. Tumor Microenvironment in Glioma Invasion. Brain Sci. 2022;12(4):505.
Akhtar MS, Swamy MK, Umar A, Al Sahli AA. Biosynthesis and Characterization of Silver Nanoparticles from Methanol Leaf Extract of Cassia didymobotyra and Assessment of Their Antioxidant and Antibacterial Activities. J Nanosci Nanotechnol. 2015;15(12):9818-9823.
Thabit AK, L. CJ, Nicolau DP. Antimicrobial resistance: impact on clinical and economic outcomes and the need for new antimicrobials. Expert Opin Pharmacother. 2015;16(2):159-177.
Wong IY, Bhatia SN, Toner M. Nanotechnology: emerging tools for biology and medicine. Genes Dev. 2013;27(22):2397-2408.
Senthilnathan B. A Comprehensive Review on Disease Related Applications of Nanotechnology. EAS J Pharm Pharmacol. 2023;5:98-104.
Rehan F, Zhang M, Fang J, Greish K. Therapeutic Applications of Nanomedicine: Recent Developments and Future Perspectives. Molecules. 2024;29(9):2073.
Chakraborty A, Mohapatra Saswati S, Barik S, Roy I, Gupta B, Biswas A. Impact of nanoparticles on amyloid β-induced Alzheimer’s disease, tuberculosis, leprosy and cancer: a systematic review. Biosci Rep. 2023;43(2).
Lu W, Chen H, Liu T, Hu J, Zhu L, Tao X, et al. Serine-modified silver nanoparticle porous spray membrane: A novel approach to wound infection prevention and inflammation reduction. Int J Pharm. 2025;670:125120.
Mojtahedi F, Nasiri MR, Ali SN, Mohammadgholi A, Mohebbi S, Shahbazi Z, et al. Novel chitosan-alginate dressings with UIO-66-NH2 nanoparticles and ferula gummosa extracts for effective wound healing. Colloids Surf A Physicochem Eng Asp. 2025;719:137004.
Amiri F, Alishahi F, Mohammadifar G, Izadidehkordi S, Charmduzi F, Dialameh F, et al. Enhanced Anticancer Efficacy of Selenium Nanoparticles Encapsulated in Niosomes: A Novel Therapeutic Strategy. Indian J Clin Biochem. 2025.
Ata Te, Al-Ani I, Karameh N, Atta MR, Dayyih WA. Alectinib-Loaded Chitosan–Alginate Nanoparticles: A Novel Synthesis Method with In Vitro and In Vivo Evaluations. Pharmaceutics. 2025;17(4):492.
Saberian E, Jenčová J, Jenča A, Jenča A, Salehipoor F, Zare-Zardini H, et al. Bleomycin-loaded folic acid-conjugated nanoliposomes: a novel formulation for targeted treatment of oral cancer. Front Bioeng Biotechnol. 2025;13.
Fathalizadeh M, Homayouni Tabrizi M, Tehranipour M. A novel alpha-terpineol-loaded niosome formulation coated with hyaluronic acid and evaluation of its anticancer properties in vitro. J Mol Liq. 2025;424:127139.
Anwar M, Rehman M, Ur-Rehman T, Khan MI, Ahmed N, Madni A, et al. Ternary lipids-based novel thermoresponsive lipid nanoparticles for targeting doxorubicin to breast cancer cells. J Pharm Sci. 2025;114(6):103723.
Sabra MS, Allam EAH, El-Aal MA, Hassan NH, Mostafa A-HM, Ahmed AAN. A novel pharmacological strategy using nanoparticles with glutathione and virgin coconut oil to treat gentamicin-induced acute renal failure in rats. Naunyn Schmiedebergs Arch Pharmacol. 2025;398(1):933-950.
Cai Y, Qiao M, Xie X, Zhou Y, Yu R, Song F, et al. Intracellular MRSA-targeted lipid-polymer hybrid nanoparticles for macrophage reprogramming and intracellular MRSA eradication. Chem Eng J. 2025;505:159665.
Nematalla HA, Elharoun M, Bargash SN, Abd-Alhaseeb MM, Sharafeldin HA, Zewail M, et al. Novel Nose-to-brain delivery of carbenoxolone via mucoadhesive solid lipid nanoparticles for Parkinson’s symptoms management: In vitro and in vivo evaluation in a rotenone-induced rat model. Int J Pharm. 2025;670:125197.
Müller EK, Białas N, Epple M, Hilger I. Nanoparticles Carrying NF-κB p65-Specific siRNA Alleviate Colitis in Mice by Attenuating NF-κB-Related Protein Expression and Pro-Inflammatory Cellular Mediator Secretion. Pharmaceutics. 2022;14(2): 419.
Gawel AM, Singh R, Debinski W. Metal-Based Nanostructured Therapeutic Strategies for Glioblastoma Treatment—An Update. Biomedicines. 2022;10(7):1598.
Hu Y. Application of nanomaterials for the treatment of glioblastoma. Trans Mater Biotechnol Life Sci. 2024;7:414-419.
Kerr BN, Duffy D, McInerney CE, Hutchinson A, Dabaja I, Bazzi R, et al. Evaluation of Radiosensitization and Cytokine Modulation by Differentially PEGylated Gold Nanoparticles in Glioblastoma Cells. Int J Mol Sci. 2023;24(12):10032.
Kostka K, Sokolova V, El-Taibany A, Kruse B, Porada D. The Application of Ultrasmall Gold Nanoparticles (2 nm) Functionalized with Doxorubicin in Three-Dimensional Normal and Glioblastoma Organoid Models of the Blood-Brain Barrier. 2024;29(11).
Allen NC, Chauhan R, Bates PJ, O’Toole MG. Optimization of Tumor Targeting Gold Nanoparticles for Glioblastoma Applications. Nano-materials. 2022;12(21):3869.
Durand M, Chateau A, Jubréaux J, Devy J, Paquot H, Laurent G, et al. Radiosensitization with gadolinium chelate-coated gold nanoparticles prevents aggressiveness and invasiveness in glioblastoma. Int J Nanomedicine. 2023:243-261.
Durand M, Lelievre E, Chateau A, Berquand A, Laurent G, Carl P, et al. The detrimental invasiveness of glioma cells controlled by gadolinium chelate-coated gold nanoparticles. Nanoscale. 2021;13(20):9236-9251.
He C, Ding H, Li L, Chen J, Mo X, Ding Y, et al. Gold nanoparticles enhance the ability of radiotherapy to induce immunogenic cell death in glioblastoma. Int J Nanomedicine. 2023:5701-5712.
Kulkarni M, Nadendla K, Pai A, Ashili S, Maibach H, Manikkath J. Lipid nanoparticles for the treatment of glioblastoma multiforme: Current status of research and clinical translation. J Drug Deliv Sci Technol. 2025;108:106891.
Brüßeler MMT, Zam A, Moreno-Zafra VM, Rouatbi N, Hassuneh OWM, Marrocu A, et al. Polyinosinic/ Polycytidylic Lipid Nanoparticles Enhance Immune Cell Infiltration and Improve Survival in the Glioblastoma Mouse Model. Mol Pharm. 2024;21(12):6339-6352.
Chang L, Zhang Y, Li M, Zhao X, Wang D, Liu J, et al. Nanostructured lipid carrier co-delivering paclitaxel and doxorubicin restrains the proliferation and promotes apoptosis of glioma stem cells via regulating PI3K/Akt/mTOR signaling. Nanotechnology. 2021;32(22):225101.
Pashirova TN, Nemtarev AV, Buzyurova DN, Shaihutdinova ZM, Dimukhametov MN, Babaev VM, et al. Terpenes-Modified Lipid Nanosystems for Temozolomide, Improving Cytotoxicity against Glioblastoma Human Cancer Cells In Vitro. Nanomaterials. 2024;14(1):55.
Shumer-Elbaz M, Ad-El N, Chulanova Y, Brier D, Goldsmith M, Bismuth M, et al. Low-frequency ultrasound-mediated blood-brain barrier opening enables non-invasive lipid nanoparticle RNA delivery to glioblastoma. J Control Release. 2025;385:114018.
Ruan S, Zhou Y, Jiang X, Gao H. Rethinking CRITID Procedure of Brain Targeting Drug Delivery: Circulation, Blood Brain Barrier Recognition, Intracellular Transport, Diseased Cell Targeting, Internalization, and Drug Release. 2021;8(9):2004025.
De Gaetano F, Cristiano MC, Venuti V, Crupi V, Majolino D, Paladini G, et al. Rutin-Loaded Solid Lipid Nanoparticles: Characterization and In Vitro Evaluation. Molecules. 2021;26(4):1039.
Battaglia L, Dianzani C, Muntoni E, Marini E, Bozza A, Bordano V, et al. Ultrasmall solid lipid nanoparticles as a potential innovative delivery system for a drug combination against glioma. Nanomedicine. 2025;20(1):37-52.
Ak G, Ünal A, Karakayalı T, Özel B, Selvi Günel N, Hamarat Şanlıer Ş. Brain-targeted, drug-loaded solid lipid nanoparticles against glioblastoma cells in culture. Colloids Surf B Biointerfaces. 2021;206:111946.
Baghel YS, Bhattacharya S. Lipid Polymeric Hybrid Nanoparticles: Formulation Techniques and Effects on Glioblastoma. Pharm Sci. 2022;28(2):174-193.
Rehman M, Madni A, Shi D, Ihsan A, Tahir N, Chang KR, et al. Enhanced blood brain barrier permeability and glioblastoma cell targeting via thermoresponsive lipid nanoparticles. Nanoscale. 2017;9(40):15434-15440.
Tan B, Liu S, Wang F, Yu Y, Sun T. Applications of polymeric nanoparticles in drug delivery for glioblastoma. Front Pharmacol. 2025;15.
Xiao X, Teng F, Shi C, Chen J, Wu S, Wang B, et al. Polymeric nanoparticles—Promising carriers for cancer therapy. Front Bioeng Biotechnol. 2022;10.
Ghasempour E, Hesami S, Movahed E, Keshel SH, Doroudian M. Mesenchymal stem cell-derived exosomes as a new therapeutic strategy in the brain tumors. 2022;13(1):527.
Dhar D, Ghosh S. A review of recent advances in magnetic nanoparticle-based theranostics of glioblastoma. 2022;17(2):107-132.
Lin J, Lin Z, Liu L, Lin W, Xie X, Zhang X. Enhancing glioma-specific drug delivery through self-assembly of macrophage membrane and targeted polymer assisted by low-frequency ultrasound irradiation. Mater Today Bio. 2024;26:101067.
Paranthaman S, Goravinahalli Shivananjegowda M, Mahadev M, Moin A, Hagalavadi Nanjappa S. Nanodelivery Systems Targeting Epidermal Growth Factor Receptors for Glioma Management. 2020;12(12).
Zhang H, Jiang W, Song T, Song M, Liu S, Zhou J, et al. Lipid-Polymer Nanoparticles Mediate Compart-mentalized Delivery of Cas9 and sgRNA for Glioblastoma Vasculature and Immune Reprogramming. 2024;11(32): e2309314.
Ding M, Zhu A, Zhang Y, Liu J, Lin L, Wang X, et al. Neutrophil-based Trojan horse containing polymer nano-therapeutics for sono-activatable ferroptosis-immunotherapy of orthotopic glioma. Nano Today. 2024;57:102398.
López Ruiz A, Bartomeu Garcia C, Navarro Gallón S, Webster TJ. Novel Silver-Platinum Nanoparticles for Anticancer and Antimicrobial Applications. 2020;15:169-179.
Skóra B, Masicz M, Nowak P, Lachowska J, Sołtysek P, Biskup J, et al. Suppression of sonic hedgehog pathway-based proliferation in glioblastoma cells by small-size silver nanoparticles in vitro. 2023;97(9):2385-2398.
Soroushnasab H, Gharbavi M, Eskandari M, Rezaeejam H, Ghorbani R, Johari B. Methotrexate-conjugated silver nanoparticles enhance chemoradiotherapy effects on U87 human glioblastoma multiforme cells: As a radiosensitizer agent to improve X-irradiation efficacy. J Drug Deliv Sci Technol. 2025;107:106791.
Goswami S, Verma Y, Rana SVS. Nanoparticles of silver and titanium can increase temozolomide sensitivity against human glioblastoma: an in vitro study on apoptosis and inflammation. Naunyn Schmiedebergs Arch Pharmacol. 2025.
Plotnikov EV, Drozd AG, Artamonov AA, Larkina MS, Belousov MV, Lomov IV, et al. Silver nanoparticles enhance neutron radiation sensitivity in cancer cells: An in vitro study. Nanomedicine. 2025;65:102813.
Eugenio M, Campanati L, Müller N, Romão LF, de Souza J, Alves-Leon S, et al. Silver/silver chloride nanoparticles inhibit the proliferation of human glioblastoma cells. Cyto-technology. 2018;70(6):1607-1618.
Cen J, Dai X, Zhao H, Li X, Hu X,
Wu J, et al. Doxorubicin-Loaded Liposome with the Function of “Killing Two Birds with One Stone” against Glioma. ACS Appl Mater Interfaces. 2023;15.
Chen H, Huang J, Wang H, Xu Y, Chen J, Deng T, et al. Multifunctional liposome boosts glioma ferroptosis and immunotherapy through reinforcement of chemo-dynamic therapy strategy. Mater Today Bio. 2025;31:101521.
Cheng Y, Zhu K, Yang L, Mao M, Wu Y, Xuan M, et al. A Self-Homing Liposomal Nanobot for Active Therapy of Glioblastoma. Angew Chem Int Ed. 2025;64:e202512948.
Zhang H-Q, Wang Y, Geng X, Dong M, Liu Z, Sun C, et al. ANG-Modified Liposomes Coloaded With α-Melittin and Resveratrol Induce Apoptosis and Pyroptosis in Glioblastoma Cells by Impeding Wnt/β-Catenin Signaling. CNS Neurosci Ther. 2025;31(5):e70437.
Knežević NŽ, Kaluđerović GN. Silicon-based nanotheranostics. Nanoscale. 2017;9(35):12821-12829.
Nik A, Zare H, Razavi S, Mohammadi H, Torab-Ahmadi P, Yazdani N, et al. Smart Drug Delivery: Capping Strategies for Mesoporous Silica Nanoparticles. Microporous Mesoporous Mater. 2020;299:110115.
Mundžić M, Ultimo A, Mladenović M, Pavlović A, Gobbo OL, Ruiz-Hernandez E, et al. Chlorotoxin-functionalized mesoporous silica nanoparticles for pH-responsive paclitaxel delivery to Glioblastoma multiforme. Heliyon. 2025;11(1).
Zhu H, Ni X, Su J, Qin Y, He X, Liu B, et al. Multifunctional Mesoporous Silicon Nanoparticles for MRI-Based Diagnostic Imaging and Glioma Therapy. ACS Appl Mater Interfaces. 2025.
Nozhat Z, Wahab A, Mushtaq A, Iqbal MZ, Kong X. Metformin loaded Mn3O4@SiO2 core–shell nanoparticles for glioblastoma multiforme targeted therapy. Colloids Surf B Biointerfaces. 2025;254: 114789.
Hsu T-I, Chen Y-P, Zhang R-L, Chen Z-A, Wu C-H, Chang W-C, et al. Overcoming the Blood–Brain Tumor Barrier with Docetaxel-Loaded Mesoporous Silica Nanoparticles for Treatment of Temozolomide-Resistant Glioblastoma. ACS Appl Mater Interfaces. 2024;16(17):21722-21735.
Qiao R, Fu C, Forgham H, Javed I, Huang X, Zhu J, et al. Magnetic iron oxide nanoparticles for brain imaging and drug delivery. Adv Drug Deliv Rev. 2023;197:114822.
Caro C, Paez-Muñoz JM, Pernía Leal M, Carayol M, Feijoo-Cuaresma M, García-Martín ML. Metabolically-Driven Active Targeting of Magnetic Nanoparticles Functionalized with Glucuronic Acid to Glioblastoma: Application to MRI-Tracked Magnetic Hyperthermia Therapy. Adv Healthc Mater. 2025;14(3):2404391.
Ghadiri M, Vasheghani-Farahani E, Atyabi F, Kobarfard F, Mohamadyar-Toupkanlou F, Hosseinkhani H. Transferrin-conjugated magnetic dextran-spermine nanoparticles for targeted drug transport across blood-brain barrier. J Biomed Mater Res A. 2017;105(10):2851-2864.
Beola L, Iturrioz-Rodríguez N, Pucci C, Bertorelli R, Ciofani G. Drug-Loaded Lipid Magnetic Nanoparticles for Combined Local Hyperthermia and Chemotherapy against Glioblastoma Multiforme. ACS Nano. 2023;17(18):18441-18455.
Aslan TN. Cationic Micelle-like Nanoparticles as the Carrier of Methotrexate for Glioblastoma Treatment. Molecules. 2024;29(24): 5977.
Maliyakkal N, Appadath Beeran A, Udupa N. Nanoparticles of cisplatin augment drug accumulations and inhibit multidrug resistance transporters
in human glioblastoma cells. Saudi
Pharm J. 2021;29(8):857-873.
Lajous H, Riva R, Lelièvre B, Tétaud C, Avril S, Hindré F, et al. Hybrid Gd3+/cisplatin cross-linked polymer nanoparticles enhance platinum accumulation and formation of DNA adducts in glioblastoma cell lines. Biomater Sci. 2018;6(9):2386-2409.
Ren Y, Yang H, Xu D, Zhang Z, Gao S, Yu R. Application of Multifunctional Metal Nanoparticles in the Treatment of Glioma. Int J Nanomedicine. 2025;20:625-638.
Suwannasing C, Suwannasom N, Iamcharoen P, Dokkham R, Maun P, Srisai P, et al. Albumin-Coated Copper Oxide Nanoparticles for Radiosensitization of Human Glioblastoma Cells Under Clinically Relevant X-Ray Irradiation. Nanomaterials. 2025;15(17):1376.
Parsaei S, Yaghoobi H, Beshkar P, Khonakdar Sangdehi HA, Khosravi Farsani MR, Safari O. Zingerone based green synthesized sodium doped zinc oxide nanoparticles eliminate U87 glioblastoma cells by inducing apoptosis. Sci Rep. 2025;15(1):13516.
Minaei SE, Khoei S, Khoee S, Mahdavi SR. Sensitization of glioblastoma cancer cells to radiotherapy and magnetic hyperthermia by targeted temozolomide-loaded magnetite tri-block copolymer nanoparticles as a nanotheranostic agent. Life Sci. 2022;306:120729.
Minchenko DO, Rudnytska OV, Khita OO, Kulish YV, Viletska YM, Halkin OV, et al. Expression of DNAJB9 and some other genes is more sensitive to SWCNTs in normal human astrocytes than glioblastoma cells. Endocr Regul. 2023;57(1):162-172.
Das S, Roy S, Dinda SC, Bose A, Mahapatra C, Basu B, et al. Carbon nanotubes in brain targeted drug delivery: A comprehensive review. Results Chem. 2025;15:102206.
Karadag B, Zeybekler SE, Gelen SS, Sabour-Takanlou L, Sabour-Takanlou M, Biray Avci C, et al. Electrodeposition of carbon nanotubes and conjugation of arginyl-glycyl-aspartic acid for the following of glioblastoma cells on bionanocomposites. Bioelectrochemistry. 2025;164:108937.
Groualle FE, Onion D, Watts JA, Rance GA, Noy A, Coyle B, et al. Bioelectronic Modulation of Glioblastoma via Wireless Carbon Nanotube Porin Interfaces. bioRxiv. 2025:2025.07.04.663176.
Pareek A, Kumar D, Pareek A, Gupta MM. Advancing Cancer Therapy with Quantum Dots and Other Nanostructures: A Review of Drug Delivery Innovations, Applications, and Challenges. Cancers. 2025;17(5):878.
Pandey SN, Afzal M, Goyal A, Padma Priya G, Mohanty B, Goyal K, et al. Quantum dot biosensors for Glioblastoma: Merging nanotechnology with precision oncology. Inorg Chem Commun. 2025;179:114671.
Fuster E, Candela H. A Transcriptomic Analysis of T98G Human Glioblastoma Cells after Exposure to Cadmium-Selenium Quantum Dots Mainly Reveals Alterations in Neuroinflammation Processes and Hypothalamus Regulation. Int J Mol Sci. 2022;23(4).
Cabral Filho PE, Cardoso AL, Pereira MI, Ramos AP, Hallwass F, Castro MM, et al. CdTe quantum dots as fluorescent probes to study transferrin receptors in glioblastoma cells. Biochim Biophys Acta. 2016;1860(1 Pt A):28-35.
Kregielewski K, Fraczek W. Graphene Quantum Dots for Glioblastoma Treatment and Detection-Systematic Review. Int J Mol Sci. 2025;30(12).
Bhogale D, Mazahir F, Yadav AK. Recent Synergy of Nanodiamonds: Role in Brain-Targeted Drug Delivery for the Management of Neurological Disorders. J Clust Sci. 2022;59(8):4806-4824.
Chen Z, Yuan SJ, Li K, Zhang Q, Li TF, An HC, et al. Doxorubicin-polyglycerol-nanodiamond conjugates disrupt STAT3/IL-6-mediated reciprocal activation loop between glioblastoma cells and astrocytes. J Control Release. 2020;320:469-483.
Elsayyad NME, Elkady OA, Swidan MM, Rashed HM, Sakr TM, Abdelhamid AM, et al. Zonisamide nanodiamonds for brain targeting: A comprehensive study utilising in silico, in vitro, in vivo, and molecular investigation for successful nose-to-brain delivery for epilepsy management. Drug Deliv Transl Res. 2025.
Nikfar B, Musavi M, Chaichian S, Guo G, Momtazi-Borojeni AA. Nanomotor-mediated drug delivery with efficient blood–brain barrier crossing for active targeting and therapy of glioblastomas: a systematic review. Nanoscale. 2025;17(28):16592-16608.
Ye J, Fan Y, Kang Y, Ding M, Niu G, Yang J, et al. Biomimetic Dual-Driven Heterojunction Nanomotors for Targeted Catalytic Immunotherapy of Glioblastoma. Adv Funct Mater. 2025;35(9):2416265.
Wang H, Lan D, Cao H, Zhao W, Gui H, Han Z, et al. Self-Propulsion of Biomimetic Nanomotors Promotes Diffusion and Convection Transport for Enhanced Radiotherapy in Solid Glioblastoma. J Am Chem Soc. 2025;147(28):25072-25087.
Escudero A, Hicke FJ, Lucena-Sánchez E, Pradana-López S, Esteve-Moreno JJ, Sanz-Álvarez V, et al. Glucose-Fueled Gated Nanomotors: Enhancing In Vivo Anticancer Efficacy via Deep Drug Penetration into Tumors.
ACS Nano. 2025;19(22):20932-20955.
Gowda BHJ, Ahmed MG, Almoyad MAA, Wahab S, Almalki WH, Kesharwani P. Nanosponges as an Emerging Platform for Cancer Treatment and Diagnosis. Adv Funct Mater. 2024;34(7):2307074.
Yin Y, Tian N, Deng Z, Wang J, Kuang L, Tang Y, et al. Targeted Microglial Membrane-Coated MicroRNA Nanosponge Mediates Inhibition of Glioblastoma. ACS Nano. 2024;18(42):29089-29105.
Fan N, Bian X. Hierarchical self-uncloaking CRISPR-Cas13a-customized RNA nanococoons for spatial-controlled genome editing and precise cancer therapy. Sci Adv. 2022;8(20):eabn7382.
Bruns J, Egan T, Mercier P, Zustiak SP. Glioblastoma spheroid growth and chemotherapeutic responses in single and dual-stiffness hydrogels. Acta Biomater. 2023;163:400-414.
Adiguzel S, Karamese M, Kugu S, Kacar EA, Esen MF, Erdogan H, et al. Doxorubicin-loaded liposome-like particles embedded in chitosan/hyaluronic acid-based hydrogels as a controlled drug release model for local treatment of glioblastoma. Int J Biol Macromol. 2024;278(Pt 4):135054.
Isik S, Yucel D, Hasirci V. Development of a Hydrogel Platform with GBM and Microglia: A Potential Glioblastoma Tumor Model. ACS Appl Bio Mater. 2025;8(9):7757-7770.
Ponomareva N, Brezgin S, Karandashov I, Kostyusheva A, Demina P, Slatinskaya O, et al. Swelling, Rupture and Endosomal Escape of Biological Nanoparticles Per Se and Those Fused with Liposomes in Acidic Environment. Pharmaceutics. 2024;16(5):667.
Cai X, Drummond CJ, Zhai J, Tran N. Lipid Nanoparticles: Versatile Drug Delivery Vehicles for Traversing the Blood Brain Barrier to Treat Brain Cancer. Adv Funct Mater. 2024;34 (41):2404234.
Marrocco F, Falvo E, Mosca L, Tisci G, Arcovito A, Reccagni A, et al. Nose-to-brain selective drug delivery to glioma via ferritin-based nanovectors reduces tumor growth and improves survival rate. Cell Death Dis. 2024;15(4):262.
Cai Y, Li W, Li M, Yao C, Zhao Y. The “All-in-One” Colorimetric System for In Situ Synthesis of Gold Nanoparticles and Mercury Detection Assisted by Nonthermal Microplasma. IEEE Trans Instrum Meas. 2024;73:1-6.
Khotimah H, Rahmaniar FZ, Zahra FA, Anaqah R, Nandar S. Unveiling the effects of nanoparticles-based antiepileptic drugs: Systematic review of in vivo studies. Heliyon. 2024.
Karami MH, Abdouss M, Rahdar A, Pandey S. Graphene quantum dots: Background, synthesis methods, and applications as nanocarrier in drug delivery and cancer treatment: An updated review. Inorg Chem Commun. 2024;161:112032.
Ali BH, Khoee S, Mafakheri F, Sadri E, Mahabadi VP, Karimi MR, et al. Active targeted delivery of theranostic thermo/pH dual-responsive magnetic Janus nanoparticles functionalized with folic acid/fluorescein ligands for enhanced DOX combination therapy of rat glioblastoma. J Mater Chem B. 2024;12(24):5957-5973.
Mineart KP, Kelley EG. Size reduction, purification, sterilization and storage/packaging of liposomes. In: Antimisiaris SG, editor. Liposomes in Drug Delivery. Academic Press; 2024. p. 489-515.
Littrell CA, Takacs GP, Sankara CS, Sherman A, Rubach KA, Garcia JS, et al. Systemically targeting monocytic myeloid-derived suppressor cells using dendrimers and their cell-level biodistribution kinetics. J Control
Release. 2024;374:181-193.
Heidari R, Assadollahi V, Khosravian P, Mirzaei SA, Elahian F. Engineered mesoporous silica nanoparticles, new insight nanoplatforms into effective cancer gene therapy. Int J Biol Macromol. 2023;253:127060.
Ye M, Gong J, Chen W, Liu X, Zhu D. Effect of the size of nucleic acid delivery systems on their fate in cancer treatment. Explor Drug Sci. 2024;2(1):38-49.
Amanat MA, Farrukh A, Ishaq MUBM, Bin Shafqat B, Haidri SH, Amin R, et al. The Potential of Nanotechnology to Replace Cancer Stem Cells. Curr Stem Cell Res Ther. 2024;19(6):820-831.
Nozhat Z, Wang S, Mushtaq A, Deng T, Iqbal MZ, Kong X. Temozolomide loaded Fe3O4@SiO2 nanoparticles for MR-imaging directed synergistic therapy of glioblastoma multiforme in vitro. Mater Today Commun. 2024;38:108289.
Kumar M, Kumar D, Mahmood S, Singh V, Chopra S, Hilles AR, et al. Nanotechnology-driven wound healing potential of asiaticoside: A comprehensive review. RSC Pharm. 2024.
Priyadarshini S, Bora S, Kulhari H. Lipid-Based Nanocarriers for the Delivery of Phytoconstituents. In: Pooja D, Kulhari H, editors. Nanotechnology Based Delivery of Phytoconstituents and Cosmeceuticals. Singapore: Springer Nature Singapore; 2024. p. 125-167.
Yasir M, Mishra R, Tripathi AS, Maurya RK, Shahi A, Zaki MEA, et al. Theranostics: a multifaceted approach utilizing nano-biomaterials. Discov Nano. 2024;19(1):35.
Nozhat Z, Heydarzadeh S, Shahriari-Khalaji M, Wang S, Iqbal MZ, Kong X. Advanced biomaterials for human glioblastoma multiforme (GBM) drug delivery. Biomater Sci.
;11(12):4094-4131.
Askarizadeh A, Mashreghi M, Mirhadi E, Mirzavi F, Shargh VH, Badiee A, et al. Doxorubicin-loaded liposomes surface engineered with the matrix metalloproteinase-2 cleavable polyethylene glycol conjugate for cancer therapy. Cancer Nanotechnol. 2023;14(1):18.
Quinn JF, Whittaker MR, Davis TP. Glutathione responsive polymers and their application in drug delivery systems. Polym Chem. 2017;8(1):97-126.
Silvarrey C, Alvite G, Esteves A. Nanoparticle formulation for the development of a dog nanovaccine against Cystic Echinococcosis. Biologicals. 2024;85:101737.
Mak IW, Evaniew N, Ghert M. Lost in translation: animal models and clinical trials in cancer treatment. Am J Transl Res. 2014;6(2):114-118.
Kwan K, Schneider JR, Kobets A, Boockvar JA. Targeting Epidermal Growth Factor Receptors in Recurrent
Glioblastoma Via a Novel Epithelial Growth Factor Receptor-Conjugated Nanocell Doxorubicin Delivery System. Neurosurgery. 2018;82(3): N23-N4.
Biau J, Durando X, Boux F, Molnar I, Moreau J, Leyrat B, et al. NANO-GBM trial of AGuIX nanoparticles with radiotherapy and temozolomide in the treatment of newly diagnosed Glioblastoma: Phase 1b outcomes and MRI-based biodistribution. Clin Transl Radiat Oncol. 2024;48:100833.
Kumthekar P, Ko CH, Paunesku T, Dixit K, Sonabend AM, Bloch O, et al. A first-in-human phase 0 clinical study of RNA interference–based spherical nucleic acids in patients with recurrent glioblastoma. Sci Transl Med. 2021;13(584):eabb3945.
Clarke JL, Molinaro AM, DeSilva AA, Rabbitt JE, Drummond DC, Chang SM, et al. A phase I trial of intravenous liposomal irinotecan in patients with recurrent high-grade gliomas. J Clin Oncol. 2015;33(15_suppl):2029.
